Effects of dextromethorphan as add-on to sitagliptin on blood glucose and serum insulin concentrations in individuals with type 2 diabetes mellitus: a randomized, placebo-controlled, double-blinded, multiple crossover, single-dose clinical trial
J Marquard, A Stirban, F Schliess, F Sievers, A Welters, S Otter, A Fischer, S Wnendt, T Meissner, T Heise, E Lammert, J Marquard, A Stirban, F Schliess, F Sievers, A Welters, S Otter, A Fischer, S Wnendt, T Meissner, T Heise, E Lammert
Abstract
In this clinical trial, we investigated the blood glucose (BG)-lowering effects of 30, 60 and 90 mg dextromethorphan (DXM) as well as 100 mg sitagliptin alone versus combinations of DXM and sitagliptin during an oral glucose tolerance test (OGTT) in 20 men with T2DM. The combination of 60 mg DXM plus 100 mg sitagliptin was observed to have the strongest effect in the OGTT. It lowered maximum BG concentrations and increased the baseline-adjusted area under the curve for serum insulin concentrations in the first 30 min of the OGTT (mean ± standard deviation 240 ± 47 mg/dl and 8.1 ± 6.1 mU/l/h, respectively) to a significantly larger extent than did 100 mg sitagliptin alone (254 ± 50 mg/dl and 5.8 ± 2.5 mU/l/h, respectively; p < 0.05) and placebo (272 ± 49 mg/dl and 3.9 ± 3.0 mU/l/h, respectively; p < 0.001). All study drugs were well tolerated, alone and in combination, without serious adverse events or hypoglycaemia. Long-term clinical trials are now warranted to investigate the potential of the combination of 30 or 60 mg DXM and dipeptidyl peptidase-4 inhibitors in the treatment of individuals with T2DM, in particular as preclinical studies have identified the β-cell protective properties of DXM.
Trial registration: ClinicalTrials.gov NCT01936025.
Keywords: DPP-IV inhibitor; NMDA; antidiabetic drug; insulin secretion; type 2 diabetes.
© 2015 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Figures
References
- Marquard J, Otter S, Welters A et al. Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment. Nat Med 2015; 21: 363–372.
- Wollheim CB, Maechler P. Beta cell glutamate receptor antagonists: novel oral antidiabetic drugs? Nat Med 2015; 21: 310–311.
- Ahrén B. Use of DPP‐4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes Metab Syndr Obes 2010; 3: 31–41.
- Rosenstock J, Zinman B. Dipeptidyl peptidase‐4 inhibitors and the management of type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2007; 14: 98–107.
- Cefalu WT, Buse JB, Del Prato S et al. Beyond metformin: safety considerations in the decision‐making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum. Diabetes Care 2014; 37: 2647–2659.
- Kahn SE, Carr DB, Faulenbach MV, Utzschneider KM. An examination of beta‐cell function measures and their potential use for estimating beta‐cell mass. Diabetes Obes Metab 2008; S4: 63–76.
- Gheni G, Ogura M, Iwasaki M et al. Glutamate acts as a key signal linking glucose metabolism to incretin/cAMP action to amplify insulin secretion. Cell Rep 2014; 9: 661–673.
- Maechler P, Wollheim CB. Mitochondrial glutamate as a messenger in glucose‐induced insulin exocytosis. Nature 1999; 402: 685–689.
- Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD‐5). Diabetes Care 2014; 37: 2149–2158.
- Farilla L, Bulotta A, Hirshberg B et al. Glucagon‐like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144: 5149–5158.
Source: PubMed